for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Ridgeback Says Approval By FDA Allows Co To Initiate Human Clinical Testing Of Eidd-2801 In U.S.

April 6 (Reuters) -

* RIDGEBACK BIOTHERAPEUTICS - CO, DRUG INNOVATIONS AT EMORY ANNOUNCED U.S. FDA APPROVED INVESTIGATIONAL NEW DRUG APPLICATION FOR EIDD-2801

* RIDGEBACK BIOTHERAPEUTICS - APPROVAL BY FDA ALLOWS CO TO INITIATE HUMAN CLINICAL TESTING OF EIDD-2801 IN UNITED STATES Source text for Eikon: Further company coverage: [ ]

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up